Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pipsa Saharinen

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
The Journal of Clinical Investigation|May 3, 2003
Double target for tumor mass destructionPipsa Saharinen, Kari Alitalo
The Journal of Biological Chemistry|September 28, 2002
The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transductionPipsa Saharinen, Olli Silvennoinen
Experimental Cell Research|March 19, 2013
Angiopoietin signaling in the vasculatureLauri Eklund, Pipsa Saharinen
The Journal of Clinical Investigation|May 25, 2011
The yin, the yang, and the angiopoietin-1Pipsa Saharinen, Kari Alitalo
The EMBO Journal|April 2, 2015
Blocking integrin inactivation as an anti-angiogenic therapyPipsa Saharinen, Johanna Ivaska
Annals of the New York Academy of Sciences|May 22, 2004
Molecular regulation of lymphangiogenesisPipsa Saharinen, Tatiana V Petrova
Current Opinion in Hematology|April 9, 2010
How do angiopoietins Tie in with vascular endothelial growth factors?Pipsa Saharinen, Maija Bry, Kari Alitalo
Nature Reviews. Drug Discovery|May 23, 2017
Therapeutic targeting of the angiopoietin-TIE pathwayPipsa Saharinen, Lauri Eklund, Kari Alitalo
Molecular Biology of the Cell|April 11, 2003
Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domainPipsa Saharinen, Mauno Vihinen, Olli Silvennoinen
Clinical Science (London, England : 1979)|December 13, 2016
Angiopoietin-Tie signalling in the cardiovascular and lymphatic systemsLauri Eklund, Jaakko Kangas, Pipsa Saharinen
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
The Journal of Clinical Investigation|May 3, 2003
Double target for tumor mass destructionPipsa Saharinen, Kari Alitalo
The Journal of Biological Chemistry|September 28, 2002
The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transductionPipsa Saharinen, Olli Silvennoinen
Experimental Cell Research|March 19, 2013
Angiopoietin signaling in the vasculatureLauri Eklund, Pipsa Saharinen
The Journal of Clinical Investigation|May 25, 2011
The yin, the yang, and the angiopoietin-1Pipsa Saharinen, Kari Alitalo
The EMBO Journal|April 2, 2015
Blocking integrin inactivation as an anti-angiogenic therapyPipsa Saharinen, Johanna Ivaska
Annals of the New York Academy of Sciences|May 22, 2004
Molecular regulation of lymphangiogenesisPipsa Saharinen, Tatiana V Petrova
Current Opinion in Hematology|April 9, 2010
How do angiopoietins Tie in with vascular endothelial growth factors?Pipsa Saharinen, Maija Bry, Kari Alitalo
Nature Reviews. Drug Discovery|May 23, 2017
Therapeutic targeting of the angiopoietin-TIE pathwayPipsa Saharinen, Lauri Eklund, Kari Alitalo
Molecular Biology of the Cell|April 11, 2003
Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domainPipsa Saharinen, Mauno Vihinen, Olli Silvennoinen
Clinical Science (London, England : 1979)|December 13, 2016
Angiopoietin-Tie signalling in the cardiovascular and lymphatic systemsLauri Eklund, Jaakko Kangas, Pipsa Saharinen
Pageof 6